Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo) (NCT06088290)
Randomized, Controlled, Open-label, Phase III Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Patients With Metastatic Leiomyosarcoma
🩺 Plain-English Summary (8th-Grade Level)
The primary objective of this phase III trial is to evaluate whether the combination of lurbinectedin plus doxorubicin given as first line treatment for metastatic leiomyosarcoma (LMS) prolongs the progression-free survival (PFS) by Independent Review Committee (IRC) when compared to doxorubicin administered as a single agent.
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic Hospital - Phoenix — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (97 Sites)
Showing the first 25 of 97 sites.
- Mayo Clinic Hospital - Phoenix — Phoenix, Arizona
- Precision NextGen Oncology & Research Center — Beverly Hills, California
- Cedars-Sinai Medical Center — Los Angeles, California
- Norris Comprehensive Cancer Center — Los Angeles, California
- Sarcoma Oncology Center — Los Angeles, California
- Stanford University (Leland Stanford Junior University) — Palo Alto, California
- University of Colorado Hospital - Anschutz Medical Campus — Aurora, Colorado
- Mayo Clinic - Jacksonville — Jacksonville, Florida
- Moffitt Cancer Center — Tampa, Florida
- Augusta University Georgia Cancer Center — Augusta, Georgia
- Massachusetts General Hospital — Boston, Massachusetts
- Dana-Farber Cancer Institute — Boston, Massachusetts
- University of Michigan — Ann Arbor, Michigan
- Mayo Clinic - Rochester — Rochester, Minnesota
- Washington University School of Medicine in St. Louis — St Louis, Missouri
- Memorial Sloan Kettering Cancer Center - New York — New York, New York
- Cleveland Clinic Main Campus — Cleveland, Ohio
- Oregon Health and Science University — Portland, Oregon
- University of Pennsylvania Abramson Cancer Center — Philadelphia, Pennsylvania
- University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center — Pittsburgh, Pennsylvania
- Vanderbilt - Ingram Cancer Center — Nashville, Tennessee
- UT Southwestern Harold C. Simmons Comprehensive Cancer Center — Dallas, Texas
- University of Texas MD Anderson Cancer Center — Houston, Texas
- Fred Hutchinson Cancer Center - Seattle Cancer Care Alliance (SCCA) Location — Seattle, Washington
- Universitaetsklinikum Graz - Universitätsklinik für Innere Medizin — Graz,
📞 Contact the Study Coordinator
Phone: (800) 664-4580
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Leiomyosarcoma
- A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma — Basking Ridge, New Jersey
- Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma — Los Angeles, California
- Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery — Phoenix, Arizona
- A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions — Houston, Texas
- Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma — Santa Monica, California
Explore by condition: All Leiomyosarcoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.